Stock UTHR UNITED THERAPEUTICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
233.8 USD -0.89% Intraday chart for United Therapeutics Corporation -1.71% +6.35%
Apr. 23 United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing MT
Apr. 23 United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,865 6,746 9,731 12,674 10,333 11,005 - -
Enterprise Value (EV) 1 3,977 5,711 9,637 12,513 8,039 7,700 6,869 5,458
P/E ratio -36.9 x 13.2 x 21.5 x 18.5 x 11.1 x 9.76 x 9.5 x 8.99 x
Yield - - - - - - - -
Capitalization / Revenue 2.67 x 4.55 x 5.77 x 6.55 x 4.44 x 4.08 x 3.9 x 3.56 x
EV / Revenue 2.74 x 3.85 x 5.72 x 6.46 x 3.45 x 2.85 x 2.44 x 1.76 x
EV / EBITDA -28.1 x 8.87 x 15.9 x 12.1 x 6.49 x 5.51 x 4.78 x 3.53 x
EV / FCF -13.7 x 8.2 x 20.2 x 18.9 x 10.8 x 7.2 x 5.97 x 4.11 x
FCF Yield -7.3% 12.2% 4.95% 5.3% 9.3% 13.9% 16.8% 24.3%
Price to Book 1.39 x 1.99 x 2.67 x 2.67 x 1.73 x 1.6 x 1.38 x 1.21 x
Nbr of stocks (in thousands) 43,881 44,441 45,037 45,577 46,994 47,059 - -
Reference price 2 88.08 151.8 216.1 278.1 219.9 233.8 233.8 233.8
Announcement Date 2/26/20 2/24/21 2/24/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,449 1,483 1,686 1,936 2,328 2,699 2,818 3,094
EBITDA 1 -141.7 643.5 605.8 1,031 1,238 1,398 1,437 1,547
EBIT 1 -187.6 593.6 555.9 979.7 1,185 1,436 1,475 1,601
Operating Margin -12.95% 40.02% 32.98% 50.6% 50.91% 53.19% 52.35% 51.75%
Earnings before Tax (EBT) 1 -165 638.9 593.9 950.6 1,274 1,490 1,582 1,689
Net income 1 -104.5 514.8 475.8 727.3 984.8 1,195 1,231 1,304
Net margin -7.21% 34.71% 28.23% 37.56% 42.31% 44.29% 43.67% 42.15%
EPS 2 -2.390 11.54 10.06 15.00 19.81 23.96 24.61 26.01
Free Cash Flow 1 -290.3 696.4 477.4 663.7 747.6 1,070 1,151 1,326
FCF margin -20.04% 46.95% 28.32% 34.28% 32.12% 39.65% 40.83% 42.88%
FCF Conversion (EBITDA) - 108.22% 78.8% 64.37% 60.38% 76.53% 80.09% 85.77%
FCF Conversion (Net income) - 135.28% 100.34% 91.26% 75.91% 89.52% 93.49% 101.73%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/26/20 2/24/21 2/24/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 444.7 415.2 461.9 466.9 516 491.5 506.9 596.5 609.4 614.7 623.3 688.3 712.7 719.2 -
EBITDA 241.1 182.4 300.5 214.5 327.2 188.8 297.7 326.3 340.3 273.8 - - - - -
EBIT 1 228.7 169.8 288 201.8 314.3 175.6 284.4 313.4 327 260.1 335.2 371.2 383.5 377.3 -
Operating Margin 51.43% 40.9% 62.35% 43.22% 60.91% 35.73% 56.11% 52.54% 53.66% 42.31% 53.77% 53.92% 53.8% 52.46% -
Earnings before Tax (EBT) 1 204.4 140.5 308.7 150.6 312.5 178.8 291.9 335.2 351.8 295.4 358.3 380 394.5 387.8 -
Net income 1 162.7 112.2 239.9 116 239.3 132.1 240.9 259.2 267.6 217.1 280.6 308.1 319.6 306.4 -
Net margin 36.59% 27.02% 51.94% 24.84% 46.38% 26.88% 47.52% 43.45% 43.91% 35.32% 45.01% 44.75% 44.84% 42.6% -
EPS 2 3.420 2.350 5.030 2.410 4.910 2.670 4.860 5.240 5.380 4.360 5.642 6.079 6.306 5.988 -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/24/22 5/4/22 8/3/22 11/2/22 2/22/23 5/3/23 8/2/23 11/1/23 2/21/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 112 - - - - - - -
Net Cash position 1 - 1,035 94.8 161 2,294 3,305 4,136 5,547
Leverage (Debt/EBITDA) -0.7876 x - - - - - - -
Free Cash Flow 1 -290 696 477 664 748 1,070 1,151 1,327
ROE (net income / shareholders' equity) -3.75% 16.7% 12.9% 16.6% 18.3% 16.8% 15.2% 13.5%
ROA (Net income/ Total Assets) 15.6% 12.1% 9.85% 13% 14.9% 14.8% 13.7% 12.5%
Assets 1 -671.4 4,264 4,832 5,607 6,606 8,082 8,965 10,405
Book Value Per Share 2 63.40 76.40 81.00 104.0 127.0 146.0 170.0 193.0
Cash Flow per Share 2 -4.720 16.90 12.60 16.50 19.70 23.50 23.90 28.70
Capex 1 83.7 59.3 121 139 230 211 242 200
Capex / Sales 5.78% 4% 7.17% 7.17% 9.9% 7.83% 8.59% 6.46%
Announcement Date 2/26/20 2/24/21 2/24/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
233.8 USD
Average target price
285.5 USD
Spread / Average Target
+22.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-16.98% 10.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Financials United Therapeutics Corporation